XOMA Royalty to merge with Generation Bio for $29m.

XOMA Royalty, the biotech royalty aggregator, agreed to merge with Generation Bio, genetic medicines company that is focused on developing gene therapies, for $29m. Generation Bio stockholders in possession of approximately 15% of Generation Bio common stock have signed support agreements under which such stockholders agreed to tender their shares in the Offer and support the merger. The acquisition is expected to close in February 2026.